Ropharma S.A.
ISIN: ROIAFRACNOR4 | Ticker: RPH | LEI: 2138004ATSD4SVFAZ789
Country: Romania
ROPHARMA S.A. BRASOV is a pharmaceutical company resulted from the union of IassyFarm S.A. Iasi, Aesculap S.A. Targu Mures, Medica S.A. Bacau and Global Pharmaceuticals S.R.L. Brasov. The company operates based on an integrative business model:
- Distribution of pharmaceutical and parapharmaceutical products from warehouses of the 5 subsidiaries in Bucharest, Iasi, Bacau, Targu Mures and Cluj Napoca;
- Retailing using the company’s own pharmacy chain, counting 129 pharmacies spread all over the country in Iasi, Vaslui, Suceava, Botosani, Bacau, Neamt, Vrancea, Mures, Harghita, Brasov, Sibiu, Prahova, Alba, Cluj;
- Drugs, dietary supplements and formula manufacturing at S.C. Aesculap Prod S.R.L. (Targu Mures), S.C. Eurofarmaco S.A. (Chisinau) and S.C. Bioef S.R.L. (Dostat Alba).
- Medical services in Sfantul Constantin multidepartamental private practice hospital, Brasov.
1952
Served areaRomania
HeadquartersStr. Iuliu Maniu, Nr. 55, Etaj 1, 500002 Brasov – Romania
| Line item in (ron) | 02.01.2020 | 01.01.2021 | 02.01.2021 | 01.01.2022 |
|---|---|---|---|---|
| Assets | N/A | 651,165,256.00 | N/A | 667,337,065.00 |
| Noncurrent Assets | N/A | 291,475,647.00 | N/A | 302,243,086.00 |
| Property Plant And Equipment | N/A | 185,166,403.00 | N/A | 187,772,664.00 |
| Investment Property | N/A | 10,126,267.00 | N/A | 10,804,637.00 |
| Goodwill | N/A | 11,613,659.00 | N/A | 11,167,579.00 |
| Intangible Assets Other Than Goodwill | N/A | 21,581,490.00 | N/A | 22,718,590.00 |
| Other Noncurrent Financial Assets | N/A | 146,709.00 | N/A | 1,001.00 |
| Current Assets | N/A | 359,689,609.00 | N/A | 365,093,979.00 |
| Cash and cash equivalents | N/A | 14,659,434.00 | N/A | 10,659,838.00 |
| Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | N/A | 9,963,160.00 | N/A | 0.00 |
| Equity And Liabilities | N/A | 651,165,257.00 | N/A | 667,337,068.00 |
| Equity | 188,589,163.00 | 201,872,388.00 | 201,872,388.00 | 219,590,190.00 |
| Issued Capital | N/A | 68,698,617.00 | N/A | 68,698,617.00 |
| Retained Earnings | N/A | 49,346,634.00 | N/A | 56,734,828.00 |
| Share Premium | N/A | 2,021,064.00 | N/A | 2,021,064.00 |
| Treasury Shares | N/A | 147,635.00 | N/A | 133,513.00 |
| Capital Reserve | N/A | 56,243,776.00 | N/A | 66,184,630.00 |
| Noncontrolling Interests | N/A | 4,001,386.00 | N/A | 7,123,168.00 |
| Liabilities | N/A | 449,292,869.00 | N/A | 447,746,878.00 |
| Noncurrent Liabilities | N/A | 90,915,167.00 | N/A | 87,818,138.00 |
| Deferred Tax Liabilities | N/A | 8,832,083.00 | N/A | 7,992,543.00 |
| Longterm Borrowings | N/A | 35,720,904.00 | N/A | 27,338,589.00 |
| Current Liabilities | N/A | 358,377,702.00 | N/A | 359,928,740.00 |
| Current Provisions | N/A | 904,173.00 | N/A | 309,978.00 |
| Current Government Grants | N/A | 266,604.00 | N/A | 249,561.00 |
| Current Payables On Social Security And Taxes Other Than Income Tax | N/A | 4,229,778.00 | N/A | 4,345,512.00 |
| Current Tax Liabilities Current | N/A | 3,550.00 | N/A | 541,453.00 |
| Line item in (ron) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
|---|---|---|
| Revenue | 716,274,771.00 | 776,685,951.00 |
| Other Income | 94,619,284.00 | 113,586,935.00 |
| Changes In Inventories Of Finished Goods And Work In Progress | -93,182.00 | 385,599.00 |
| Cost Of Merchandise Sold | 621,772,625.00 | 682,780,330.00 |
| Employee Benefits Expense | 95,954,389.00 | 108,002,620.00 |
| Depreciation Expense | 22,690,307.00 | 23,151,046.00 |
| Other Gains Losses | -80,055.00 | N/A |
| Profit Loss From Operating Activities | 12,219,343.00 | 18,651,013.00 |
| Finance Income | 674,607.00 | 1,394,749.00 |
| Finance Costs | 6,256,482.00 | 6,516,296.00 |
| Profit Loss Before Tax | 6,637,468.00 | 13,529,466.00 |
| Profit Loss From Continuing Operations | 4,636,175.00 | 11,570,948.00 |
| Profit (loss) | 6,753,489.00 | 10,728,725.00 |
| Profit Loss Attributable To Owners Of Parent | 6,753,489.00 | 10,728,725.00 |
| Profit Loss Attributable To Noncontrolling Interests | -2,117,314.00 | 842,223.00 |
| Line item in (ron) | 01.01.2021 | 01.01.2022 |
|---|---|---|
| Profit (loss) | 6,753,489.00 | 10,728,725.00 |
| Adjustments For Decrease Increase In Inventories | 12,109,774.00 | -15,483,150.00 |
| Adjustments For Depreciation And Amortisation Expense | 22,690,307.00 | 23,151,046.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | -29,620.00 | -945,915.00 |
| Cash Flows From Used In Operations | -8,831,418.00 | 1,433,419.00 |
| Interest Paid Classified As Operating Activities | 3,262,996.00 | 3,221,056.00 |
| Interest Received Classified As Operating Activities | 131,719.00 | 16,445.00 |
| Income Taxes Paid Refund Classified As Operating Activities | 1,343,266.00 | 2,618,347.00 |
| Cash Flows From Used In Operating Activities | -10,174,684.00 | -1,184,928.00 |
| Other Cash Payments To Acquire Interests In Joint Ventures Classified As Investing Activities | 2,602,051.00 | 947,493.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 11,914,452.00 | 17,189,638.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 2,432,233.00 | 1,442,566.00 |
| Purchase Of Other Longterm Assets Classified As Investing Activities | 33,623.00 | 0.00 |
| Cash Flows From Used In Investing Activities | -16,135,854.00 | -12,334,687.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 9,625,895.00 | 10,392,128.00 |
| Cash Flows From Used In Financing Activities | -10,453,801.00 | -24,468,340.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | -36,764,339.00 | -37,987,955.00 |
| Cash and cash equivalents | 14,659,434.00 | 10,659,838.00 |
Please note that some sums might not add up.
ROIAFRACNOR4
LEI2138004ATSD4SVFAZ789
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.